No significant pharmacokinetic interaction occurs between selegiline and cabergoline,pramipexole or ropinirole.
Clinical evidence,mechanism, importance and management
Dostert P,Benedetti MS, Persiani S, La Croix R, Bosc M, Fiorentini F, Deffond D, Vernay D,Dordain G. Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. J Neural Transm (1995) 45 (Suppl), 247–57.
Mirapexin (Pramipexole). Boehringer Ingelheim Ltd. UK Summary of product characteristics,August 2006.
SmithKline Beecham. Personal Communication,September 1996.